CBD drug manufacturer GW Pharmaceuticals saw a significant net loss in the last quarter, despite growth and sales of its cannabis-derived pharmaceutical drugs going to plan.

The company reported a loss of $71.9m for the quarter ending 31st December 2018, compared with $61.8m for the same quarter in 2017.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us